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Accidental overdosing of NSAIDs is relatively common in animals, especially dogs, and it can 
induce ARF. In humans, ARF is generally defined as an 
abrupt and sustained decrease in renal function that 
leads to an accumulation of nitrogenous waste products 
and uremic toxins.1 However, indicators (such as serum 
creatinine and urea concentrations) routinely used to 
evaluate renal function will increase above reference 
values only after severe renal damage, and there is a delay 
in this increase. These indicators can also be affected by 
factors other than renal insufficiency. Therefore, early 
biomarkers of AKI are needed to enable clinicians to 
detect patients with injury or at risk for ARF because 
of an overdose of an NSAID, which will allow for early 
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Objective—To	evaluate	early	indicators	of	renal	tissue	destruction	and	changes	in	urinary	
enzyme	 activities	 in	 sheep	 during	 the	 first	 hours	 after	 acute	 kidney	 injury	 induced	 by	
administration	of	an	overdose	of	an	NSAID.
Animals—12	adult	female	sheep.
Procedures—Acute	kidney	injury	was	induced	in	6	sheep	by	administration	of	ketoprofen	
(30	mg/kg,	 IV)	and	detected	by	evaluation	of	urinary	protein	concentration,	 iohexol	clear-
ance,	and	results	of	histologic	examination.	Six	sheep	served	as	control	animals.	Blood	and	
urine	samples	were	collected	for	up	to	24	hours	after	administration	of	ketoprofen.	Plasma	
concentrations	of	urea,	creatinine,	albumin,	and	total	protein;	plasma	activities	of	alkaline	
phosphatase,	 acid	 phosphatase,	 γ-glutamyl	 transpeptidase	 (GGT),	 matrix	 metalloprotein-
ase	(MMP)-2,	and	MMP-9;	and	urinary	creatinine	and	protein	concentrations,	specific	grav-
ity,	and	activities	of	alkaline	phosphatase,	acid	phosphatase,	GGT,	lactate	dehydrogenase,	
N-acetyl-β-D-glucosaminidase	(NAG),	MMP-2,	and	MMP-9	were	measured.	Urinary	protein	
concentration	 and	 enzyme	 activities	 were	 normalized	 on	 the	 basis	 of	 urinary	 creatinine	
concentrations	and	reported	as	ratios.
Results—Many	urinary	enzyme-to-creatinine	ratios	increased	before	the	plasma	creatinine	
concentration	exceeded	the	reference	value.	Urine	NAG,	lactate	dehydrogenase,	and	acid	
phosphatase	activities	were	 increased	beginning	at	2	hours	after	ketoprofen	administra-
tion,	and	alkaline	phosphatase,	GGT,	and	MMP-2	activities	were	increased	beginning	at	4	
hours	after	ketoprofen	administration.	Most	peak	urinary	enzyme-to-creatinine	ratios	were	
detected	earlier	than	were	the	highest	plasma	creatinine	and	urea	concentrations.
Conclusions and Clinical Relevance—Urinary	 enzyme	 activities	 were	 sensitive	 early	
indicators	of	acute	kidney	injury	induced	by	an	overdose	of	an	NSAID	in	sheep.	(Am J Vet 
Res	2010;71:1246–1252)
therapeutic intervention. An ideal indicator can be 
measured rapidly from a single urine sample without 
the need to collect urine for 24 hours.
Activities of a variety of enzymes, such as GGT,2–4 
ALP,2,3 LDH,2 and NAG,2–7 have been evaluated in urine 
as biomarkers of AKI in humans, and they have been 
used to evaluate nephrotoxicosis in dogs.8 Increases of 
urinary GGT and NAG activities have been suggested 
as indicators of early renal damage in dogs with diro-
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AbbreviAtions
ACP	 Acid	phosphatase
AKI	 Acute	kidney	injury
ALP	 Alkaline	phosphatase
ARF	 Acute	renal	failure
GGT	 γ-Glutamyl	transpeptidase
HPLC	 High-performance	liquid	chromatography
LDH	 Lactate	dehydrogenase
MMP	 Matrix	metalloproteinase
NAG	 N-acetyl-β-D-glucosaminidase
TBS	 Tris-buffered	saline
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filariasis (ie, heartworm disease)9 and leishmaniasis.10 
In 1 study,11 ALP and GGT were sensitive early indica-
tors of nephrotoxic damage experimentally induced by 
administration of mercuric chloride in sheep. The ACP 
activity in renal tissue has been investigated after ex-
perimentally induced tubular injury.12 The gelatinases, 
MMP-2 and -9, have been localized to the renal tubules, 
interstitial cells, and tubulointerstitial space.13 Urinary 
total gelatinolytic activity, comprising both MMP-2 and 
-9, was increased in humans with diabetic nephropathy, 
compared with activity in healthy control subjects.14 
The gelatinases also may play a role in AKI because 
MMP-9 has been associated with AKI6 and MMP-2 and 
-9 activities are enhanced in postischemic kidney tissue 
in rats.13 Only limited information exists describing the 
detection of enzyme activities in urine during the early 
phases of clinical or experimentally induced AKI.6,7,11
The primary objective of the study reported here 
was to evaluate noninvasive indicators of renal tissue 
destruction that could be used to predict the risk of 
AKI as early as possible after an overdose of an NSAID 
before increases in plasma concentrations of creatinine 
and urea would suggest renal insufficiency. A second 
objective was to determine changes in urinary enzyme 
activities during the first hours after induction of AKI 
by administration of an overdose of an NSAID (ie, keto-
profen). Acute renal failure was detected by evaluation 
of traditional markers, such as urinary protein concen-
tration that indicated increased glomerular permeabil-
ity, glomerular filtration rate that reflected decreased re-
nal function, and results of histologic examination that 
revealed morphological changes. We hypothesized that 
increases in enzyme activities in urine would indicate 
tissue destruction before the first signs of renal failure 
were detected.
Materials and Methods
Animals—Twelve female Finnish Landrace sheep 
were purchased from a commercial breeder for use in 
the study. All sheep were > 18 months old and were 
not pregnant. Body weight ranged from 48.5 to 59.0 kg 
(mean, 52.5 kg). The sheep had previously been used 
in a pharmacodynamic study, but they had not received 
clinical doses of medications for 4 months before the 
onset of the study reported here, and we presumed that 
the medications administered in that previous study did 
not cause irreversible lesions. The sheep were provided ad 
libitum access to good-quality hay and water before and 
during the experiment. At the start of the experiment, the 
sheep were healthy and were not receiving any treatments. 
No changes indicative of renal disease were detected in 
plasma or urine. The study protocol was approved by the 
Ethics Committee of the University of Helsinki.
Study design and procedures—Each sheep was 
allocated to a treatment or control group (n = 6 sheep/
group) by use of a simple randomization procedure (ie, 
by drawing lots). The 6 sheep in the treatment group 
were each administered an overdose of ketoprofena (30 
mg/kg, IV). The ketoprofen was injected into a jugu-
lar vein, and the contralateral jugular vein was used for 
collection of blood samples. The 6 sheep in the control 
group did not receive any injection.
Blood samples (9 mL) were collected into tubes con-
taining lithium heparin before treatment (time 0 [base-
line]) and at 1, 2, 4, 6, 8, and 24 hours. Urine samples 
(10 mL) were collected before treatment (baseline) and 
at 2, 4, 6, and 8 hours via a urinary catheterb inserted 
into the bladder. After collection of the urine sample at 
8 hours, the catheter was removed. The next day, after 
collection of the blood sample at 24 hours and perform-
ing the iohexol test, each sheep was anesthetized by IV 
administration of xylazine hydrochloridec (0.2 mg/kg) 
and ketamine hydrochlorided (5 mg/kg). Sheep then were 
euthanatized by IV administration of a solution of em-
butramide and mebezoniumiodide.e A final urine sample 
(ie, sample at 24 hours) was collected via cystocentesis 
immediately after the sheep were euthanatized.
Laboratory assays—Blood and urine samples were 
kept in ice water until centrifuged (1,300 X g for 10 min-
utes at 4oC) to remove cellular components and debris. 
Plasma and urine supernatant were harvested. Plasma 
concentrations of urea, creatinine, albumin, and total pro-
tein and activities of aspartate aminotransferase, ALP, ACP, 
and GGT and urine concentrations of creatinine and pro-
tein and activities of GGT, ALP, and LDH were measured 
by use of a clinical chemistry analyzer.f Urine specific 
gravity was determined via refractometry. The remainder 
of the plasma and urine samples was frozen at –80oC until 
subsequent use of plasma and urine in MMP-2, MMP-9, 
and ACP assays and use of urine in an NAG assay. Ac-
tivities of ACP were analyzed with a commercial kit,g and 
urinary NAG activity was measured with a commercial 
kith by use of a colorimetric method.
Activities of MMP-2 and -9 were measured via semi-
quantitative gelatin zymography, SDS-PAGE electrophore-
sis, and western blotting. Purification of urinary gelatin-
ases was performed as described elsewhere,15 with slight 
modifications. Briefly, 20-mg creatinine-equivalent urine 
samples were mixed with 200 µL of gelatin-sepharose 
beadsi equilibrated with binding buffer (50mM Tris [pH, 
7.5], 0.5M NaCl, 10mM CaCl
2
, 0.01% Tween 20, and 
5mM EDTA) and incubated overnight at 4oC with gentle 
rotation. The beads then were extensively washed, and the 
bound material was eluted with electrophoresis loading 
buffer. Plasma samples were diluted with distilled deion-
ized water (1 part plasma:5 parts distilled deionized wa-
ter) to minimize the effect of plasma proteins on detection 
of bands with gelatin zymography. Plasma and urinary 
MMP activities were measured by use of gelatin zymo-
graphy.16 The samples were loaded into the wells of a 10% 
gelatin gel.j For each gel, 3 concentrations of purified hu-
man MMP-2 and -9 mixturek as well as prestained protein 
standardl were assayed in parallel with the samples. After 
electrophoresis, gels were incubated with renaturing buf-
fer (2.5% Triton X-100) for 30 minutes at 20oC with gentle 
rotation. Thereafter, the gels were incubated with develop-
ing buffer (50mM Tris-HCl [pH, 7.5], 0.02M NaCl, 5mM 
CaCl
2
, and 0.02% polyoxyethylene lauryl ether) overnight 
at 37oC. After incubation, gels were stained with Coo-
massie Brilliant Blue R-250, which revealed clear bands 
against a blue background. Gels were photographed, and 
density of the bands was measured with a spot-density 
tool of an imaging system.m A standard curve was cre-
ated on the basis of the values for the standard mixtures, 
and samples obtained from the sheep were quantified by 
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comparing their mean pixel value (after background cor-
relation) with values for the standard curve. Results were 
reported as intensities of the gelatinolytic bands.
Native PAGE electrophoresis and SDS-PAGE elec-
trophoresis were performed on ice with 10% gels and 
Tris-glycine buffer (pH, 8.3) at 125 V for 90 minutes, 
as described elsewhere.17 Proteins were transferred 
onto a polyvinylidene fluoride membranen by use of a 
transfer apparatus.o Nonspecific binding was reduced 
by incubating blots in blocking buffer (5% nonfat dry 
milk, 0.1% Tween 20, and 1X TBS) for 1 hour at 20oC. 
Immunodetection was performed by incubating blots 
with a mouse anti-human MMP-218,p or goat anti- 
human MMP-9p primary antibody at appropriate dilu-
tion in a buffer of 1X TBS plus 0.1% Tween 20. Blots then 
were washed 3 times with 1X TBS plus 0.1% Tween 20 
and incubated with horseradish peroxidase–conjugated 
goat anti-mousek or donkey anti-goatk primary anti-
body in 1X TBS plus 0.1% Tween 20 (dilution, 1:5,000) 
for 3 hours at 20oC. After the third wash, detection of 
the signal was achieved by use of an enhanced chemilu-
minescent substrate,q and the signal was evaluated with 
a luminescent image analyzer.r
To correct for variations in urine flow, urinary pro-
tein concentration and enzyme activities were normal-
ized on the basis of urinary creatinine concentrations. 
Results were reported as ratios.
An iohexol test was performed twice (2 to 4 weeks 
before and 24 hours after treatment). Iohexols was admin-
istered (3.0 g/sheep, IV) into a jugular vein, and blood 
samples were collected from the contralateral jugular vein 
at 2, 3, and 4 hours after injection. For iohexol analysis, 
	 	 	 	 	 Time	(h)
Variable	 Group	 Baseline	 2	 4	 6	 8	 24
Creatinine (mmol/L) Ketoprofen 17.8  10.9 7.2 3.9 2.7 2.7
  (8.0–21.8) (3.7–16.6) (4.5–10.1)*†  (2.2–7.9)*†  (1.4–6.5)*†  (2.2–3.5)†
 Control 12.4  13.4 14.9 15.3 12.8 9.1
  (8.9–14.9)  (10.9–25.4) (6.3–27.1)  (12.7–25.6)  (6.6–24.8)  (2.1–20.0)
Protein-to-creatinine   Ketoprofen 0.11  0.96 7.72 18.0 27.2 3.76
  ratio (g/g)  (0.09–0.18)  (0.56–1.50)†  (4.09–19.6)*†  (6.69–63.1)*†  (3.05–112.9)*†  (0.97–16.5)†
 Control 0.14  0.49 0.78 1.41 1.36 0.77
  (0.08–0.38)  (0.18–1.38)†  (0.34–1.77)†  (0.38–2.67)†  (0.69–3.58)† (0.23–3.60)†
GGT (U/mmol) Ketoprofen 0.86  0.86 1.66 3.02 6.17 2.62
  (0.50–1.18)  (0.79–1.38)  (0.49–4.20)  (1.27–8.17)*†  (2.62–17.53)*† (0.89–16.13)
 Control 0.94  0.81 1.01 1.07 1.34 1.33
  (0.56–1.14)  (0.39–1.98) (0.37–2.95)  (0.56–3.69)  (0.40–3.35)  (0.78–2.93)
ALP (U/mmol) Ketoprofen 3.2  4.3 13.9 42.3 98.2 27.4
  (1.9–5.0) (1.9–9.7) (9.4–42.4)*† (27.7–135.8)*†  (16.2–420.8)*†  (8.7–86.3)†
 Control 3.7  4.3 5.2 5.8 9.6 8.5
  (2.6–7.4)  (1.6–10.6)  (1.4–13.2)  (2.5–18.6)  (3.0–20.1) (4.4–9.9)
ACP (U/mmol) Ketoprofen 8.3  13.9 26.8 34.4 30.9 9.5
  (7.3–9.1)*  (9.9–22.2)*†  (11.9–39.2)*†  (11.6–53.8)*†  (9.3–56.5)*† (8.7–20.5)*†
 Control 7.1  7.2 5.9 6.3 6.1 7.5
  (6.8–8.1)  (5.7–7.7)  (4.6–6.4)†  (5.3–6.8)  (5.8–8.1) (7.1–9.6)
LDH (U/mmol) Ketoprofen 0.95  5.98 51.05 87.7 185.2 105.0
  (0.12–2.77) (2.67–22.64)*† (0–150.46)† (40.2–228.2)*†  (28.2–535.4)*† (39.9–305.7)*†
 Control 0.89  1.67 2.05 2.44 1.71 8.09
  (0–4.36)  (0–2.19) (0.97–2.69) (0.68–6.88) (1.09–17.60) (0–59.33)
Proenzyme MMP-2 Ketoprofen 0  1.07 6.27 13.3 21.8 8.62
  (intensity)  (0–0.40) (0.88–2.60)†  (0.89–11.43)*†  (5.87–28.9)*†  (5.63–40.1)*†  (0.83–40.6)*†
 Control 0  0.56 0.63 1.03 0.89 0
  (0–0.00)  (0–1.29)  (0–2.00)  (0–2.40)†  (0–1.96) (0–0.62)
Activated MMP-2   Ketoprofen 0  0.10 0.56 2.64 2.70 1.47
  (intensity)  (0–0) (0–1.36) (0–1.92) (0.12–5.89)*† (0.41–9.46)*† (0–4.28)*†
 Control 0  0 0 0 0 0
  (0–0)  (0–0) (0–0) (0–0) (0–0) (0–0)
NAG (U/mmol) Ketoprofen 0.03  0.12 NM 0.73 NM 0.26
  (0.02–0.04) (0.04–0.26)*†  (0.17–1.40)*†  (0.05–0.60)*†
 Control 0.03  0.02 NM 0.02 NM 0.04
  (0.02–0.04) (0.02–0.03)   (0.02–0.04)   (0.02–0.15)
Specific gravity  Ketoprofen 1.050  1.041 1.031 1.020 1.016 1.013
  (1.028–1.055) (1.021–1.055)  (1.027–1.036) (1.016–1.030)*†  (1.014–1.019)*†  (1.012–1.016)†
 Control 1.030  1.041 1.036 1.041 1.035 1.037
  (1.023–1.044)  (1.032–1.052)†  (1.020–1.052)  (1.028–1.044)  (1.027–1.049)  (1.006–1.046)
Urine samples were collected at 0 (baseline), 2, 4, 6, and 8 hours via a urinary catheter inserted into the bladder; urine samples at 24 hours 
were collected via cystocentesis immediately after the sheep were euthanatized.
*Within a time point within a variable, value differs significantly (P  0.05) from the value for the control sheep. †Within a row, value differs 
significantly (P  0.05) from the value for baseline.
 NM = Not measured.
Table	1—Median	(range)	values	for	urinary	concentration	of	creatinine,	protein-to-creatinine	ratio,	enzyme	activity	indices	(normalized	
on	the	basis	of	urinary	creatinine	concentrations),	and	specific	gravity	in	samples	collected	from	6	sheep	after	administration	of	keto-
profen	(30	mg/kg,	IV)	and	from	6	control	sheep	that	did	not	receive	any	treatment.	
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plasma samples were precipitated with 10% trifluoroacetic 
acid and analyzed with an HPLC.19,20,t The internal stan-
dard was 4-aminobenzoic acid. Iohexol clearance was cal-
culated as described elsewhere.21
Plasma concentrations of ketoprofen were mea-
sured with an HPLC,22 with slight modifications. De-
terminations were made on 4 samples in parallel. The 
HPLC system was equipped with a piston pump,u 
autosampler,v tunable absorbance UV detector,w and 
workstation.x Sample separation was conducted on a 
4.6 X 150-mm column packed with 5 µm of reversed-
phase silica.y Flow rate of the isocratic mobile phase 
(which consisted of acetonitrile and 0.03% phosphoric 
acid [ratio, 1:1]) was 1.5 mL/min. Samples were ana-
lyzed at a wavelength of 254 nm. Accuracy and preci-
sion of the method were evaluated (as recommended in 
another study23) by analyzing 6 parallel plasma samples 
spiked with ketoprofen. The standard curve was found 
to be linear (R2 > 0.998) over the concentration range 
used (0.36 to 50 mg/L). Mean values at the extremes 
of the concentration range were 0.39 mg/L (coefficient 
of variation for accuracy and precision was 4.1% and 
8.3%, respectively) and 50.8 mg/L (4.9% and 1.7%, re-
spectively). No interfering peaks were detected for the 
plasma blanks. The elimination half-life was calculatedz 
by dividing the natural logarithm of 2 by β, where β is 
the elimination rate constant.
Histologic examination—A necropsy was per-
formed immediately after each sheep was euthanatized. 
Tissue samples for histologic examination were collect-
ed from the kidneys and placed in neutral-buffered 10% 
formalin. The fixed samples were embedded in paraffin, 
sectioned in 4-µm-thick slices, and stained with H&E, 
van Gieson, periodic acid–Schiff, and von Kossa stains 
for histologic examination via light microscopy.
Statistical analysis—Differences in iohexol clear-
ance between groups were analyzed via a Student t test. 
Because the plasma enzyme activities and urinary en-
zyme indices were not normally distributed, all differ-
ences between groups at various time points were ana-
lyzed via a Mann-Whitney U test and the values were 
compared with values at time 0 via a Wilcoxon rank 
test. Significance was set at values of P < 0.05.
Results
Urinary enzyme-to-creatinine ratios for GGT, ALP, 
ACP, LDH, proenzyme MMP-2, activated MMP-2, and 
NAG increased after administration of ketoprofen 
	 Time	(h)
Variable	 Group	 Baseline	 1	 2	 4	 6	 8	 	24
Urea (mmol/L) Ketoprofen 5.3  5.2 5.8 7.2 8.8 9.8 20.6
  (3.9–6.9) (4.1–7.0) (4.5–7.6)†  (5.6–8.8)*† (6.6–9.6)*†  (7.1–10.4)*†  (14.0–22.3)*† 
 Control 4.7  5.3 4.9 4.6 4.1 3.4 4.1
  (3.5–5.2)  (3.8–6.3)  (3.6–6.1) (3.7–5.7)  (3.4–5.7)  (2.8–5.0)  (2.6–7.2)
 
Creatinine   Ketoprofen 86  88 89 120 151 184 390
  (µmol/L)  (80–106)  (79–105)  (82–109) (100–140)*†  (131–191)*†  (150–208)*† (131–414)*†
 Control 92  96 89 91 90 88 90
  (81–113)  (80–110) (79–106) (74–101) (71–102)  (74–105) (71–101)
Albumin (g/L) Ketoprofen 31.6  31.5 30.1 29.6 29.4 28.6 26.4
  (30.8–32.6)  (31.0–32.8) (28.0–31.1)*† (28.6–30.4)*†  (28.7–31.5)*†  (27.6–31.2)*† (23.5–31.9)*†
 Control 31.8  31.9 31.6 31.6 32.6 31.8 32.0
  (30.2–33.9) (30.3–33.1)  (30.7–32.4)  (30.9–32.8) (30.1–34.4) (30.9–32.8) (30.8–33.6)
 
Total protein   Ketoprofen 64.8  64.9 62.1 60.1 60.5 57.6 51.8
  (g/L)  (61.0–68.7)  (61.0–66.5)† (59.3–63.1)*†  (56.4–60.1)*†  (54.7–66.0)*†  (52.0–65.2)*†  (42.9–68.1)*†
 Control 67.0  66.2 66.4 66.5 67.1 67.0 66.3
  (63.0–69.5)  (63.4–68.7)  (64.8–68.2) (63.7–67.9)  (63.5–72.3) (64.8–68.9) (60.9–68.3)
        
ALP (U/L) Ketoprofen 229  196 202 198 205 186 121
  (175–296) (159–296) (164–296)  (131–288)† (136–302)  (128–312)  (72–312)*†
 Control 202  212 201 186 203 201 200
  (184–337)  (199–259)  (189–252) (167–276) (187–266) (169–300) (171–300)
ACP (U/L) Ketoprofen 3.8  NM NM NM NM 9.3 7.5
  (3.4–4.1)      (5.0–11.2)*†  (4.3–10.2)*†
 Control 3.7  NM NM NM NM 3.8 3.8
  (3.5–4.0)      (3.6–4.1) (3.4–3.9)
GGT (U/L) Ketoprofen 46  44 42 43 43 40 36
  (37–69)  (36–67)  (35–65)†  (35–62)†  (36–64)  (34–59)† (30–48)*†
 Control 46  45 47 47 48 46 46
  (41–52)  (40–49)  (41–50) (41–51)  (42–50)  (42–50) (41–49)
See Table 1 for key.
Table	2—Median	(range)	values	for	plasma	concentrations	of	urea,	creatinine,	total	protein,	and	albumin	and	activities	of	ALP,	ACP,	and	
GGT	in	samples	obtained	from	6	sheep	after	administration	of	ketoprofen	(30	mg/kg,	IV)	and	from	6	control	sheep	that	did	not	receive	
any	treatment.
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(Table 1). Activity of MMP-9 was not detected in any 
urine samples obtained at time 0 or in urine samples 
obtained from the control sheep; however, MMP-9 ac-
tivity was detected in urine samples obtained from 3 of 
6 sheep after ketoprofen injection. Some urine samples 
had a reddish tint after administration of ketoprofen, 
which suggested hematuria or hemoglobinuria. Protein-
uria was detected and urine specific gravity decreased 
after administration of an overdose of ketoprofen.
Plasma ALP and GGT activities decreased and 
ACP activity increased after administration of ketopro-
fen (Table 2). Plasma MMP-2 and -9 activities did not 
change over time; in addition, they did not differ be-
tween groups (data not shown).
Plasma concentrations of urea and creatinine in-
creased after administration of ketoprofen, and they 
remained higher than in the control sheep beginning 
at 4 hours after treatment until the end of the study 
(Table 2). Plasma concentrations of creatinine were 
> 1.5 times as high as the value at time 0 in all ketopro-
fen-treated sheep from 4 to 8 hours (median, 6 hours) 
after injection until the end of the study, at which time 
they were > 3 times as high as the value at time 0 in 5 
of 6 ketoprofen-treated sheep. Plasma concentrations 
of creatinine exceeded the reference range24 for sheep 
(168 µmol/L) in 5 of 6 sheep at 6 to 8 hours (median, 
6 hours) after ketoprofen treatment. Plasma concentra-
tions of urea were higher than the reference range24 for 
sheep (7.1 mmol/L) in all 6 sheep at 24 hours after ke-
toprofen treatment. Elimination of iohexol was signifi-
cantly reduced the day after administration of ketopro-
fen; at that time, mean ± SD iohexol clearance was 3.7 
± 4.5 mL/h/kg and 23.2 ± 1.8 mL/h/kg in treated and 
control sheep, respectively.
Mean ± SD plasma concentration of ketoprofen 
was 87.5 ± 33.4 µg/mL and 22.1 ± 7.9 µg/mL at 1 and 2 
hours after administration, respectively. Mean elimina-
tion half-life of ketoprofen was 2.1 ± 0.6 hours.
Histologic examination of renal tissues collected 
from the carprofen-treated sheep revealed acute tubu-
lar injury. This was not detected in tissues collected 
from the control sheep. Lesions concerning the cortical 
region (especially the proximal tubules) included de-
generation and necrosis of individual tubular epithelial 
cells, swelling of the tubular epithelium, detachment 
of the tubular epithelium from the underlying tubular 
basement membrane, loss of the periodic acid–Schiff–
positive brush border of proximal tubular epithelial 
cells, thinning of the tubular epithelium, dilatation 
of the tubular lumina, interstial edema, sloughed epi-
thelial cells in the tubular lumens, cellular debris, and 
casts in the distal tubules (Figure 1). Other histologic 
results were consistent for both groups, and only mild 
incidental unspecific findings, such as interstitial med-
ullary calcification, were detected.
Discussion
The increase in plasma concentrations of urea and 
creatinine and the decrease in iohexol clearance in ke-
toprofen-treated sheep indicated a reduced glomerular 
filtration rate. Proteinuria suggested increased glomeru-
lar permeability attributable to an overdose of ketopro-
fen, and it was probably associated with the decrease 
in the plasma concentration of albumin. Histologic 
examination revealed ketoprofen-induced AKI. Thus, 
the dose of ketoprofen administered was sufficient to 
induce AKI in sheep. The slight increases detected in 
urinary protein concentration and proenzyme MMP-2 
activity in some sheep in the control group suggested 
that the urethral catheter, which remained in situ for 8 
hours, may have caused local irritation in the bladder, 
but catheterization did not markedly affect the other 
variables measured in the study.
The elimination half-life of ketoprofen in plasma 
was higher after the overdose of ketoprofen in the sheep 
of the present study than in sheep in other studies25,26 
after administration of a frequently used dose of race-
mic ketoprofen (3 mg/kg) or its enantiomers. Approxi-
mately 2 hours after administration of ketoprofen at a 
dose of 30 mg/kg, the plasma concentration of ketopro-
fen in our study was at the same value as the maximum 
concentration reported in sheep after administration at 
the frequently used dose of 3 mg/kg.25,26 Thus, expo-
sure to the toxic plasma concentration of ketoprofen 
Figure	 1—Photomicrographs	 of	 sections	 of	 renal	 tissues	 ob-
tained	from	a	representative	control	sheep	that	did	not	receive	
any	treatment	(A)	and	a	representative	sheep	24	hours	after	ad-
ministration	of	ketoprofen	(30	mg/kg,	IV;	B).	In	panel	A,	notice	the	
histologically	normal	tubular	epithelium	(white	arrows).	In	panel	
B,	notice	the	thinning	of	the	tubular	epithelium	(black	arrow)	and	
the	cellular	debris	in	the	tubular	lumina	(white	arrow).	H&E	stain;	
bar	=	200	µm.
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was probably relatively short, and most of the injuries 
in the tubular cells can be expected to have taken place 
during the early phase of our follow-up period.
Although the plasma concentration of creatinine 
was significantly higher than the concentration at time 
0 and the concentration in the control sheep by 4 hours 
after administration of ketoprofen, it did not exceed cri-
teria for AKI in humans (ie, a 2- to 3-fold increase from 
the baseline value)2,27 and it was not above the reference 
range for sheep24 in any of the sheep in our study until 
several hours later. Therefore, the plasma concentration 
of creatinine was not a sensitive indicator of AKI during 
the first few hours after exposure to ketoprofen.
In general, urinary enzyme-to-creatinine ratios 
seemed to be sensitive early indicators of the risk of 
AKI because many of them increased sooner than did 
the plasma concentration of creatinine. Brush border 
enzymes are typically released into the urine during less 
severe injuries, compared with release of lysosomal or 
cytosolic enzymes.3 Thus, the increases in urinary ac-
tivities of the lysosomal enzymes NAG and ACP and 
the cytosolic LDH suggested relatively severe injuries of 
tubular cells within 2 hours after administration of ke-
toprofen. In addition, the sporadic hematuria observed 
in some sheep may have contributed to the increase in 
LDH activity, which is an enzyme known to be found in 
RBCs. According to a recent systematic review,4 evalua-
tion of GGT activity performs well for early diagnosis of 
AKI in humans, and in another study11 in sheep, evalu-
ation of GGT activity appeared to be more sensitive 
than did evaluation of LDH activity after injection with 
mercuric chloride. However, in the study reported here, 
NAG, LDH, and ACP activities were increased in urine 
earlier than were activities of the brush border enzymes 
ALP and GGT, which indicated that the former may re-
veal cell injuries earlier than do the latter. On the other 
hand, the decrease in plasma ALP and GGT activities 
detected after administration of ketoprofen suggested 
that at least a part of these urinary enzyme activities 
originated from plasma. In humans, urinary NAG ac-
tivity may be useful for assessing initial malfunction 
or damage of the proximal tubular epithelial cells in 
the early stages of potentially progressive diseases.5 In 
addition, urinary NAG activity has predictive value in 
functional outcome and response to treatment,5 and 
it can be used for prediction of the risk of death after 
AKI.4 The use of LDH, ACP, and ALP activities should 
be evaluated in clinical settings.
In the study reported here, increased activities of 
proenzyme and activated MMP-2 were found in urine, 
whereas MMP-9 activity was detected only in a few 
samples. In another study6 in which MMP-2 activity 
was not measured, MMP-9 activity could not be used to 
differentiate human patients with AKI from those with 
urinary tract infection, despite the fact that MMP-9 ac-
tivity was associated with AKI. On the other hand, in 
human patients with diabetic nephropathy, MMP-9 was 
more extensively converted to the active form than was 
MMP-2 and the proportion of active MMP-9 in urine 
was significantly higher than that in healthy control 
subjects.14 These findings suggest that MMP-2 may be 
released into the urine and activated, especially during 
the acute phase of injuries to tubular cells.
Most of the urinary enzyme-to-creatinine ratios 
measured in our study were already decreasing when 
the highest plasma concentrations of creatinine and 
urea were detected at 24 hours (ie, the day after induc-
tion of AKI). This indicated a delay between cellular 
damage and the accumulation of creatinine and urea 
in plasma. Our results also suggested that peak urinary 
enzyme activities may not have been detected in a clinical 
study5 in humans because the first urine sample in that 
study was collected 24 hours or more after exposure.
In the study reported here, urinary enzyme-to-
creatinine ratios were found to have great potential 
as early biomarkers of AKI induced by an overdose 
of an NSAID. Activities of NAG, LDH, and ACP were 
increased in the urine within 2 hours after ketoprofen 
administration, and ALP and GGT activities increased 
significantly at 4 hours after ketoprofen administration. 
Activity of MMP-2 may be a better indicator of AKI than 
is activity of MMP-9. However, we did not evaluate cell 
injuries via histologic examination until the end of the 
study; thus, we could not compare the stage of the in-
jury and its progression to the urinary enzyme indices 
at the various time points. Therefore, we could not es-
timate the specificities of these enzymes as biomarkers 
of AKI and their possible cutoff points, and they should 
be investigated in clinical studies.
a. Comforion vet inj, 100 mg/mL, Orion Pharma, Espoo, Finland.
b. All-silicone Foley balloon catheter, Sewoon Medical Co, Ipjang, 
Korea.
c. Rompun, Bayer, Leverkusen, Germany.
d. Ketalar, Pfizer, Espoo, Finland.
e. T61 vet, Intervet, Boxmeer, The Netherlands.
f. Konelab 30i, Thermo Fisher Scientific Corp, Vantaa, Finland.
g. Konelab acid phosphatase, Thermo Electron Corp, Vantaa, 
Finland.
h. N-Acetyl-β-D-glucosaminidase (NAG), Roche, Mannheim, 
Germany.
i. Amersham Pharmacia Biotech, Uppsala, Sweden.
j. Ready Gel zymogram gel, Bio-Rad Laboratories, Hercules, 
Calif.
k. Chemicon International, Temecula, Calif.
l. Precision Plus protein dual color, Bio-Rad Laboratories, Hercu-
les, Calif.
m. AlphaImager HP, Alpha Innotech Corp, San Leandro, Calif.
n. Immobilin-P, Millipore, Bedford, Mass.
o. Bio-Rad Laboratories, Hercules, Calif.
p. Santa Cruz Biotechnology Inc, Santa Cruz, Calif.
q. Pierce, Rockford, Ill.
r. LAS-3000, Fuji Photo Film, Tokyo, Japan.
s. Omnipaque, Amersham Health AS, Eindhoven, The 
Netherlands.
t. Liquid chromatograph 1100/liquid chromatograph 1200, Agi-
lent Technologies, Waldbronn, Germany.
u. Waters 501, Waters Corp, Milford, Mass.
v. Waters 717 autosampler, Waters Corp, Milford, Mass.
w. Waters 486 tunable absorbance detector, Waters Corp, Milford, 
Mass.
x. Millennium 32 chromatography manager, Waters Corp, Mil-
ford, Mass.
y. SunFire C
18
, Waters Corp, Milford, Mass.
z. Kinetica software, Thermo Electron Corp, Waltham, Mass.
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